CTRI/2018/12/016607已完成3 期
A Multicentric, Randomized, Double Blind, Parallel Group, Comparative, Phase-III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Efonidipine Hydrochloride Ethanolate 20 mg and Telmisartan 40 mg Tablets Versus Efonidipine Hydrochloride Ethanolate Tablets 20 mg and Telmisartan Tablets 40 mg monotherapy in Subjects with Stage 2 Hypertension.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 249
- 试验地点
- 25
- 主要终点
- To evaluate the efficacy and safety of Efonidipine Hydrochloride Ethanolate 20 mg and Telmisartan 40 mg Tablets in Subjects with Stage 2 Hypertension
研究概览
简要总结
“A Multicentric, Randomized, Double Blind, Parallel Group,Comparative, Phase-III Clinical Study to Evaluate the Efficacy, Safety andTolerability of Efonidipine Hydrochloride Ethanolate 20 mg and Telmisartan 40 mgTablets Versus Efonidipine Hydrochloride Ethanolate Tablets 20 mg andTelmisartan Tablets 40 mg monotherapy in Subjects with Stage 2 Hypertension.â€
PrimaryObjective
· To evaluate theefficacy and safety of Efonidipine Hydrochloride Ethanolate 20 mg and Telmisartan40 mg Tablets in Subjects with Stage 2 Hypertension.
SecondaryObjective
· To evaluate thetolerability of Efonidipine Hydrochloride Ethanolate 20 mg and Telmisartan 40 mgTablets in Subjects with Stage 2 Hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Subjects meeting all of the following criteria will be recruited for the trial: 1.Male or Female subjects between 18 to 65 years of age (Both Inclusive).
- •2.Treatment-Naïve subjects who are suffering from Stage 2 Hypertension.
- •3.Subjects diagnosed with mean SBP of ≥160 to ≤180 mmHg and mean DBP ≥100 to ≤110 mmHg (3 readings will be taken by validated automated blood pressure machine in sitting position, first reading will be taken after 15 min.
- •rest and subsequent two readings will be recorded at the interval of 2 min.
- •4.Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures.
排除标准
- •Subjects will be excluded if ANY of the following conditions apply: 1.Suspected hypersensitivity to any of the ingredients of study medication.
- •2.Subjects with known case of Secondary or Malignant Hypertension.
- •3.Subjects with abnormal Renal Function Test.
- •4.Subjects with abnormal eGFR less than 60 mL/min/1.73 m2 will be excluded from the study.
- •5.Subjects with known case of bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one functioning kidney.
- •6.Subjects with hyponatremia as per blood biochemistry results at screening.
- •7.Subjects with Serum potassium more than 5.5 mEq/L or less than 3.5 mEq/L at baseline.
- •8.Subjects with abnormal Liver Function Tests.
- •9.Subjects with abnormal Thyroid Function Test.
- •10.Subjects with known case of Type 1 Diabetes will be excluded from the study.
- •11.Subjects with Type 2 Diabetes Mellitus whose diabetes has not been stable and uncontrolled for the previous three months and with HbA1c value greater than 8% will be excluded from the study.
- •12.Subjects with known case of symptomatic congestive heart failure, severe aortic stenosis, unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery, sinus node dysfunction and any clinically significant cardiac arrhythmias will be excluded from the study.
- •13.Subjects with known case of Stroke will be excluded from the study.
- •14.Subjects diagnosed or suffering from any Oncological Conditions since last 2 years will be excluded from the study.
- •15.Subjects with known case of Epileptic seizures will be excluded from the study.
- •16.Subjects with clinical history of bipolar disorder i.e. who are taking lithium.
- •17.Female subjects who are pregnant or lactating or planning to become pregnant during the study period.
- •Females who are not ready to use acceptable contraceptive methods during the course of study.
- •18.Concurrent participation in another clinical trial or any investigational therapy within 30 days prior to signing informed consent.
- •19.Currently taking prohibited concomitant medications(s) listed and inability/unwillingness to discontinue them for the entire study period.
结局指标
主要结局
To evaluate the efficacy and safety of Efonidipine Hydrochloride Ethanolate 20 mg and Telmisartan 40 mg Tablets in Subjects with Stage 2 Hypertension
时间窗: Change from baseline in mean sitting SBP at the end of study (12 weeks).
次要结局
- To evaluate the tolerability of Efonidipine Hydrochloride Ethanolate 20 mg and Telmisartan 40 mg Tablets in Subjects with Stage 2 Hypertension.(Change from baseline in mean sitting DBP at the end of study (12 weeks).)
研究者
研究点 (25)
Loading locations...
相似试验
尚未招募
3 期
A Study of Combination of Efonidipine Hydrochloride Ethanolate 20 mg/20 mg and Metoprolol Succinate ER 25 mg/ 50 mg Tablets Versus Efonidipine Hydrochloride Ethanolate Tablets 20 mg and Metoprolol Succinate ER Tablets 50 mg Monotherapy for the treatment of Hypertension.CTRI/2018/12/016625Ajanta Pharma Ltd300
尚未招募
3 期
A study of Azelnidipine Tablets 16 mg for the treatment of hypertensionCTRI/2018/10/015899Ajanta Pharma Ltd228
已完成
3 期
A Study of Combination of Azilsartan Medoxomil plus Cilnidipine Tablets for the treatment of subjects with Hypertension.CTRI/2019/07/020204Synokem Pharmaceuticals Ltd222
Unknown
3 期
A Study of Azelnidipine Tablets for the treatment of subjects with HypertensionCTRI/2019/07/020126Synokem Pharmaceuticals Ltd236
已完成
3 期
A Phase-III clinical study to compare the Efficacy, Safety and Tolerability of FDC of Telmisartan 40mg plus Bisoprolol 5 mg tablets versus FDC of Telmisartan 40mg plus Metoprolol Succinate ER 50 mg tablets in the treatment of Stage 1 and Stage 2 HypertensionCTRI/2021/11/037926Micro Labs Limited264